We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Nuformix Plc | LSE:NFX | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.20 | 0.18 | 0.20 | 1,081,377 | 08:00:17 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -859k | -0.0012 | -1.67 | 1.49M |
From Apr 2021 to Apr 2024
TIDMNFX
RNS Number : 2884G
Nuformix PLC
23 July 2021
Nuformix plc
("Nuformix" or the "Company")
Posting of Annual Report and Notice of AGM
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that its Annual Report and Accounts for the year ended 31 March 2021 and Notice of Annual General Meeting ("AGM") will be posted to shareholders later today and will be available in full to download from the Company's website (www.nuformix.com) shortly.
In accordance with the Listing Rule 9.6.1, a copy of these documents has been uploaded to National Storage Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The AGM will be held at Orega, 70 Gracechurch Street, London, EC3V 0HR on Tuesday, 24 August 2021 at 10.00am.
Shareholders should read the Notice of AGM for further details of arrangements for attendance at the AGM and voting.
Enquiries:
Nuformix plc +44 (0)1223 627222 Dr Anne Brindley, CEO Allenby Capital Limited +44 (0)203 328 5656 Nick Athanas / George Payne (Corporate Finance) Stefano Aquilino / Matt Butlin (Sales and Corporate Broking) Walbrook PR Anna Dunphy / Paul McManus / Kiki +44 (0)207 933 8780 Zaccagnini nuformix@walbrookpr.com
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NOAFIFIADAIVFIL
(END) Dow Jones Newswires
July 23, 2021 08:35 ET (12:35 GMT)
1 Year Nuformix Chart |
1 Month Nuformix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
